SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is seeing significant bullish momentum after a short-seller retracted serious allegations against a major shareholder, driving a rebound and sparking community discussion around an imminent short squeeze and anticipated strong earnings.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio Inc. is trending after the FDA issued a Complete Response Letter (CRL) for its RGX-121 gene therapy, citing trial design concerns and intensifying community discussion around the stringent regulatory environment for gene therapies. While many anticipate further stock depreciation and question the company's outlook, some investors highlight other pipeline assets as potential future drivers.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant discussion as investors grapple with its recent price action ahead of its upcoming Q4 earnings report. Community sentiment is split between those who view its AI-powered lending model as massively undervalued given its profitability and prudent risk management, and others concerned by its conservative growth outlook and the broader fintech sector's current struggles.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending following a significant sell-off after it issued weaker-than-expected revenue guidance, intensifying broader market concerns that AI tools could disrupt traditional software business models. The community is divided, with many calling the drop an overreaction and a buying opportunity, while others believe AI will render such platforms obsolete.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is gaining significant attention following its pre-announcement of substantially raised revenue guidance for fiscal year 2026, driven by strong demand in the AI infrastructure buildout. The community is actively discussing its position as a key "picks and shovels" beneficiary of massive hyperscaler capital expenditures, despite recent price volatility and ongoing debates around its core technology and insider share sales.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to its latest earnings, where a revenue miss and softer forward guidance, particularly against a backdrop of ongoing automotive market softness, have disappointed investors. Community discussion centers on the company's valuation, perceived lack of growth beyond pure AI chip plays, and the broader impact of the EV sector slowdown.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending sharply lower after the abrupt departures of its CFO and general counsel amid an accounting review and delayed regulatory filings, prompting community discussions ranging from severe financial irregularity concerns to perceptions of an extreme, oversold market reaction.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is seeing heightened discussion ahead of its earnings report, as the community debates whether its perceived undervaluation and recent insider buying will spark a rebound or if previous guidance adjustments and broader fintech sector concerns will lead to another significant decline.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is trending as a recent IPO, driving community discussion around its low float and market cap, with some anticipating a significant move higher while others expect a pullback after an initial run.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending after reporting a significant earnings beat and robust revenue guidance, sparking community discussion around its substantial advanced packaging investments for AI and compute, which are strongly supported by CHIPS Act funding.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TD Waterhouse Canada Inc. Takes $2.03 Million Position in Carlsmed, Inc. $CARL

TD Waterhouse Canada Inc. bought a new stake in Carlsmed, Inc. (NASDAQ:CARL - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 152,242...

Teacher Retirement System of Texas Purchases Shares of 175,000 Carlsmed, Inc. $CARL

Teacher Retirement System of Texas acquired a new position in Carlsmed, Inc. (NASDAQ:CARL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange...

Carlsmed (NASDAQ:CARL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Carlsmed from a "hold" rating to a "sell" rating in a report on Saturday...

CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery

Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.

Carlsmed (NASDAQ:CARL) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday...

Truist Financial Reaffirms Buy Rating for Carlsmed (NASDAQ:CARL)

Truist Financial reissued a "buy" rating and issued a $20.00 price objective (up previously from $18.00) on shares of Carlsmed in a research note on Friday...

Carlsmed (NASDAQ:CARL) Announces Earnings Results, Beats Expectations By $0.05 EPS

Carlsmed (NASDAQ:CARL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05...

Goldman Sachs has started coverage of Carlsmed with a ‘Buy’ rating and a $19 price target, suggesting about 35% upside from recent levels.The research firm’s&nbsp;analyst David Roman said the firm sees “meaningful upside” for the stock thanks to Carlsmed’s differentiated technology platform and asset-light business model,&nbsp;the Fly reported.He pointed to the company’s&nbsp;salesforce expansion, its planned 2026 launch in cervical spine procedures, and a steady flow of new clinical data as important revenue drivers.The call comes after several recent milestones. Earlier this month, the Centers for Medicare &amp; Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement for cervical fusion procedures using Carlsmed’s aprevo implants.&nbsp;Starting&nbsp;in&nbsp;October, through the NTAP program, hospitals performing these procedures will be eligible for up to an additional $21,125 in reimbursement on top of standard payments.Carlsmed also reported the first cervical procedure with its aprevo device in July at UC San Diego Health, showing progress toward a U.S. launch targeted for 2026. The company’s technology is already approved for lumbar fusion surgery and uses AI-driven planning tools to design personalized implants for patients.The company had its initial public offering on July 23, raising $100.5 million at an IPO price of $15 per share. The shares dropped 3.3% on the first day of trading, closing at $14.50, valuing the company at about $384 million.&nbsp;Since then,&nbsp;<a href="https://stocktwits.com/symbol/CARL">Carlsmed’s shares</a>&nbsp;have fallen&nbsp;6.3% year-to-date. On Friday, the stock closed 2.7% lower at $13.58 before ticking up 0.5% after hours to $13.65.Carlsmed, founded in 2018, has drawn backing from B Capital Group and US Venture Partners, which together own nearly half the company. Co-founder and Chief Executive Michael Cordonnier holds a smaller stake.&nbsp;In the first quarter of 2025, the company lost $5.7 million on $10.2 million in revenue, compared with a loss of $5.4 million on $5.1 million in revenue a year earlier.On Stocktwits, retail sentiment for Carlsmed was ‘bearish’ by late Sunday, worsening from the ‘neutral’ mood seen a day ago, amid ‘normal’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs has started coverage of Carlsmed (CARL) with a ‘Buy’ rating and a $19 price target. (Photo credit: Getty Images)

Carlsmed Stock Down 6% Since IPO But Goldman Bullish And Predicts 35% Upside Potential — Retail Traders Stay Bearish

The company’s July IPO raised $100.5 million but shares have slipped since, closing Friday at $13.58 before edging up in after-hours trade.

Equity

Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. Its solutions are utilized as an information database for surgeons using traditional surgical techniques. The company was founded by Mike Cordonnier and Niall Casey and is headquartered in Carlsbad, CA.

Carlsmed Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.42	--	--	N/A
Q3 '25	-$0.48	-$0.40	16.95%	BEAT
Q2 '25	-$1.47	-$1.47	--	EXPECTED

CARL
Carlsmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CARL News

CARLCarlsmed Inc